0001735276-21-000097.txt : 20211223 0001735276-21-000097.hdr.sgml : 20211223 20211223172308 ACCESSION NUMBER: 0001735276-21-000097 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211221 FILED AS OF DATE: 20211223 DATE AS OF CHANGE: 20211223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vaishnaw Akshay CENTRAL INDEX KEY: 0001458494 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36407 FILM NUMBER: 211518161 MAIL ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770602661 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2021-12-21 0 0001178670 ALNYLAM PHARMACEUTICALS, INC. ALNY 0001458494 Vaishnaw Akshay 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 0 1 0 0 President, R&D Common Stock 2021-12-21 4 A 0 5417 0.0 A 16632 D Common Stock 2021-12-22 4 F 0 2415 189.13 D 14217 D Common Stock 2021-12-22 4 F 0 1 190.5 D 14216 D Common Stock 2021-12-22 4 F 0 122 186.48 D 14094 D Common Stock 2021-12-23 4 S 0 124 186.22 D 13970 D Common Stock 2021-12-23 4 S 0 137 187.08 D 13833 D Common Stock 2021-12-23 4 S 0 130 187.35 D 13703 D Common Stock 2021-12-23 4 S 0 127 188.26 D 13576 D Common Stock 2021-12-23 4 S 0 73 189.01 D 13503 D Common Stock 2021-12-23 4 S 0 8 189.18 D 13495 D Common Stock 2021-12-23 4 S 0 144 189.24 D 13351 D Common Stock 2021-12-23 4 S 0 144 190.02 D 13207 D Common Stock 2021-12-23 4 S 0 5 190.27 D 13202 D Common Stock 2021-12-23 4 S 0 73 190.33 D 13129 D Common Stock 2021-12-23 4 S 0 142 190.39 D 12987 D Common Stock 2021-12-23 4 S 0 125 190.86 D 12862 D Common Stock 2021-12-23 4 S 0 1000 191.45 D 11862 D Common Stock 2021-12-23 4 S 0 73 192.25 D 11789 D Common Stock 2021-12-23 4 S 0 126 193.37 D 11663 D Common Stock 2021-12-23 4 S 0 145 193.67 D 11518 D Common Stock 2021-12-23 4 S 0 303 195.11 D 11215 D Common Stock 515 I by Managed Account On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Sale prices ranged from $191.14 to $191.80. Sale prices ranged from $194.82 to $195.43. Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. By: /s/ Mary Beth DeLena, Attorney-in-Fact For: Akshay K. Vaishnaw 2021-12-23